Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF]
Recruiting
The CHRONICLES study will investigate the change in clinical and patient reported outcomes after six-months of treatment with Budenoside/Glycopyrronium/Formoterol \[BGF\] in a real-world setting.
Gender:
ALL
Ages:
Between 35 years and 130 years
Trial Updated:
08/20/2025
Locations: Research Site, Windsor, Ontario
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Preventing Falls in Older Adults With Cognitive Frailty
Recruiting
The Problem: The proposed trial will address the problem of how to effectively prevent subsequent falls in community-dwelling cognitively frail older adults with a history of falls. Primary Question: In community-dwelling older adults with cognitive frailty and a history of falls, can a home-based exercise program with behavioural change techniques significantly reduce falls vs. health education (i.e., control; CON)?
Gender:
ALL
Ages:
Between 65 years and 89 years
Trial Updated:
08/20/2025
Locations: Centre for Aging SMART at VCH, University of BC, Vancouver, British Columbia
Conditions: Falls, Frailty, Mild Cognitive Impairment
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
Recruiting
This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/20/2025
Locations: Perelman Center for Advanced Medicine - Endocrinology, Philadelphia, Pennsylvania +6 locations
Conditions: Type 1 Diabetes, Kidney Transplant
Cirrhosis Care Alberta (CCAB): A Pragmatic Type II Hybrid Effectiveness Implementation Trial
Recruiting
Liver cirrhosis is the leading cause of morbidity and premature mortality in patients with digestive disease. There are many gaps in care which contribute to a high rate of hospital readmissions (44 percent at 90 days) and inadequate quality of care. Currently, there is a lack of structured processes to initiate best practice support for medical and broader health needs of high risk patients. The cirrhosis care Alberta program (CCAB) is a 3 year multi-component quality improvement initiative wh... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: University of Alberta, Edmonton, Alberta
Conditions: Cirrhosis, Liver
An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
Recruiting
This non-interventional study (NIS) is designed to collect information on the effectiveness and safety of treatment received in routine clinical care, as well as measure the health-related quality of life (HRQoL) of participants with Type 3 von Willebrand disease (VWD) receiving prophylactic therapy per local standard of care (SOC) over an observation period of at least 24 weeks.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
08/20/2025
Locations: UZ Leuven Gasthuisberg, Leuven, Not set +19 locations
Conditions: Von Willebrand Disease, Type 3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
Recruiting
RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Trial 2 will be led by the Canadian Cancer Trials Group (CCTG) and conducted in North America, with CCTG the regulatory sponsor in Canada, and University of Miami the regulatory sponsor and IND holder in the US. Datasets from Trial 1 and Trial 2 will... Read More
Gender:
ALL
Ages:
Between 16 years and 69 years
Trial Updated:
08/20/2025
Locations: Stanford University - (Stanford Cancer Institute), Stanford, California +61 locations
Conditions: Hodgkin Lymphoma
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
08/20/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +534 locations
Conditions: Progressive Pulmonary Fibrosis
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Recruiting
The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: Rocky Mountain Cancer Centers, Aurora, Colorado +284 locations
Conditions: Multiple Myeloma
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Recruiting
This study is open to adults who are at least 18 years old living with obesity and have: * a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis (MASH) and * moderate or advanced liver fibrosis People with a history of acute or chronic liver diseases other than MASH or chronic alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people with MASH and moderate or ad... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: The Institute for Liver Health, LLC, Flagstaff, Arizona +483 locations
Conditions: Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Recruiting
GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants with locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: Research Site, Newark, Delaware +57 locations
Conditions: Gastroesophageal Adenocarcinoma
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
Recruiting
The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/20/2025
Locations: Infirmary Cancer Center, Mobile, Alabama +218 locations
Conditions: Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
Recruiting
The main objective of the study is to characterize safety and efficacy of 2 dose levels of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded Independent Central Review (BICR).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/20/2025
Locations: City of Hope National Medical Center, Duarte, California +84 locations
Conditions: MTAP-deleted NSCLC